<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94133">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01953055</url>
  </required_header>
  <id_info>
    <org_study_id>ALOB-SATURN2013</org_study_id>
    <nct_id>NCT01953055</nct_id>
  </id_info>
  <brief_title>SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)</brief_title>
  <acronym>SATURN</acronym>
  <official_title>Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current treatment options for high risk localized prostate cancer include radical
      prostatectomy +/- postoperative radiotherapy, radical radiotherapy with androgen deprivation
      therapy. Evidence has emerged that prostate cancer has a low α/β ratio in the range of 1-3
      Gy. Even with high risk tumors, prostate cancer is hypothesized to have a greater
      sensitivity to large fraction sizes and high dose per fraction radiotherapy theoretically
      allows for biological dose escalation with fewer visits and no additional toxicity.
      Therefore, we hope to determine the toxicity, quality of life, biochemical and pathological
      control of SBRT for high risk prostate cancer incorporating ENI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute GU and GI toxicities</measure>
    <time_frame>Baseline to 3 months post treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute GU and GI toxicities as assessed using the Common Terminology for Adverse Events (CTCAE) v3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late GU and GI toxicities</measure>
    <time_frame>&gt; 6 months post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Late GU and GI toxicities as assessed using RTOG grading schema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical control</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prostate biopsy 2 years post ADT cessation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic ablative radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic ablative radiotherapy</intervention_name>
    <arm_group_label>Stereotactic ablative radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent obtained

          -  men &gt; 18 years of age

          -  histologically confirmed prostate adenocarcinoma (centrally reviewed)

          -  high risk prostate cancer, defined as at least one of clinical stage T3 or Gleason
             8-10, or PSA &gt; 20ng/mL

        Exclusion Criteria:

          -  prior pelvic radiotherapy

          -  anticoagulation medication (if unsafe to discontinue for gold seed insertion)

          -  diagnosis of bleeding diathesis

          -  large prostate (&gt;90cm3) on imaging at time of gold seed insertion

          -  no evidence of castrate resistance (defined as PSA &lt; 3ng/mL while testosterone is &lt;
             0.7nmol/L

          -  definitive regional or distant metastatic disease on staging investigations
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Loblaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre/University of Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Loblaw, MD</last_name>
    <phone>(416) 480-4806</phone>
    <email>andrew.loblaw@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Odette Cancer Centre/Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5`</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Loblaw, MD</last_name>
      <phone>(416) 480-4806</phone>
      <email>andrew.loblaw@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Loblaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bindu Musurunu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danny Vesprini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Chu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger Buckeley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stan Flax, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Rodrigues, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glenn Baumann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harvey Quon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Andrew Loblaw</investigator_full_name>
    <investigator_title>Dr. Andrew Loblaw</investigator_title>
  </responsible_party>
  <keyword>stereotactic ablative radiotherapy</keyword>
  <keyword>androgen deprivation therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
